announced on Thursday it plans to raise £94 million through an IPO on London’s AIM stock market.
The designer, manufacturer and distributor of eyewear frames will place 48.2 million shares at 195p each, raising £94 million and listing at a market capitalisation of £138 million.
Inspecs Group’s shares will trade under the ticker SPEC, and is expected to be admitted to AIM on February 27.
Robin Totterman, CEO of Inspecs said: "Today marks a truly exciting moment for Inspecs as we embark on the next stage of our growth journey in order to capitalise on the significant market opportunity that exists in the globally expanding eyewear industry.”
Inspecs was founded in 1988 as a UK-focused eyewear frame distributor, with licence agreements with companies that include and O'Neill.,
Mr. Totterman added: “We are delighted to have received a positive reception from a high quality set of investors, all of whom recognise the strong track record, differentiated proposition and competitive strengths of the business, being one of only a few companies providing a one-stop-shop to global retail chains.”
He continued: "This IPO will enable the business to fuel its growth ambitions both organically and through acquisitions, as we leverage our key strengths and competitive advantages to continue to take market share and drive shareholder value.”
Inspecs is chaired by Ian MacLaurin, who served as chair of Tesco PLC between 1985 and 1997 and Vodafone Group PLC between 1999 and 2006.
In H1 of 2019, Inspecs said its revenues climbed 14% year-on-year to £30.4 million, and expects to publish its full year results by June 30, under AIM rules.
In 2018, the company reported $57.3 million of revenues, a 17% increase from 2017.
Peel Hunt is to be Nomad, Sole Broker and Sole Bookrunner to Inspecs.
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
The investment firm, said its final results for the year ended 31 December 2019 have ‘significantly improved compared to the previous year’ as a result of its new investment strategy in listed junior companies through debt and equity linked products.
After deferring his decision to step down as CEO as a result of the coronavirus crisis, Stephen Blyth today announces his official step down from the role but says he will continue as a director in the position of Founder and non-executive Deputy Chairman.
AstraZeneca said it will be able to supply two billion doses of a potential virus vaccine following two new deals. Last month, AstraZeneca said it could manufacture one billion doses, that it is developing with scientists at Oxford University but yesterday after signing two deals, including one backed by Bill Gates, means it can double production.
Cluff said it is ‘fully committed’ to drilling a Shell-partnered North Sea prospect, but that drilling at the Selene prospect is now expected to start in 2022. Meanwhile, the Company remains fully funded for all its other planned drilling operations.